[{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Zelenoleucel","moa":"PRAME","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ US Food & Drug Administration","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ US Food & Drug Administration"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marker Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marker Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Blue Owl Capital","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Blue Owl Capital"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cellipont Bioservices","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Neldaleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marker Therapeutics \/ Marker Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Marker Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by Marker Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
